GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (STU:PCBK) » Definitions » Net Income (Continuing Operations)

Sesen Bio (STU:PCBK) Net Income (Continuing Operations) : €-17.46 Mil (TTM As of Dec. 2022)


View and export this data going back to 2016. Start your Free Trial

What is Sesen Bio Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Sesen Bio's Net Income (Continuing Operations) for the three months ended in Dec. 2022 was €-7.15 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2022 was €-17.46 Mil.


Sesen Bio Net Income (Continuing Operations) Historical Data

The historical data trend for Sesen Bio's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sesen Bio Net Income (Continuing Operations) Chart

Sesen Bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.62 -96.75 -18.41 -0.30 -18.77

Sesen Bio Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.92 -0.73 -30.23 20.66 -7.15

Sesen Bio Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sesen Bio  (STU:PCBK) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Sesen Bio Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Sesen Bio's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sesen Bio (STU:PCBK) Business Description

Industry
Traded in Other Exchanges
N/A
Address
245 First Street, Suite 1800, Cambridge, MA, USA, 02142
Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.

Sesen Bio (STU:PCBK) Headlines

From GuruFocus

Pacific Continental Corp. (PCBK) CFO Michael Reynolds sells 1,650 Shares

By GuruFocus Research GuruFocus Editor 02-22-2010

Pacific Continental Corp. (PCBK) President/COO Roger S Busse buys 1,000 Shares

By GuruFocus Research GuruFocus Editor 10-15-2009

Pacific Continental Corp. (PCBK) CEO Hal Brown buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 10-15-2009